Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis at the ECTRIMS Annual Congress
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis at the ECTRIMS Annual Congress
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.